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Background. Hypothyroidism and raised thyroid antibody levels have been associated with adverse obstetrical outcomes. Several
studies have investigated causal associations, but results have been inconsistent and few studies have reported the effects of thyroxine
replacement therapy on pregnancy outcomes in hypothyroid patients. Objective. The primary study objective was to determine the
outcome of pregnancies in women diagnosed with overt and subclinical hypothyroidism (SCH) (serum TSH > 2.5 mIU/L) and
those with elevated circulating thyroid autoantibody levels in the first trimester of pregnancy and after the institution of appropriate
thyroxine replacement therapy to maintain the serum TSH ≤ 2.5 mIU/L. Study Design. This prospective observational study was
undertaken between 2013 and 2016. Blood samples were taken from 1025 women at presentation for thyroid stimulating hormone
(TSH), anti-thyroglobulin antibodies (TGAb), and thyroid peroxidase antibodies (TPOAb). Those with a TSH > 2.5 mIU/L were
treated with thyroxine and managed appropriately to ensure that the TSH was maintained ≤2.5 mIU/L. Outcomes in these patients
were compared to those in euthyroid patients. Maternal antenatal complications and perinatal outcomes were recorded. Results.
There were a total of 1025 patients of whom 382 (37.5%) were nulliparous. 10.1% had a TSH level > 2.5 mIU/L and 18.2% had at
least one raised thyroid antibody level. No differences in adverse outcomes of pregnancy were evident in women treated for SCH
or overt hypothyroidism compared to the euthyroid group. There was also no association between raised thyroid antibodies and
adverse pregnancy outcomes in either group. Conclusion. There were no adverse outcomes of pregnancy found in pregnant women
who had been diagnosed and treated with thyroxine for SCH at the time of presentation when compared to euthyroid patients.
There was also no relationship with thyroid antibodies and adverse pregnancy outcomes in the two groups. It is not possible to
unequivocally advocate for thyroxine replacement in pregnant women with subclinical and overt hypothyroidism until large scale
randomized controlled trials are performed.

1. Introduction
Thyroid disorders are among the most common endocrine
disorders in pregnancy. The prevalence of hypothyroidism in
pregnancy varies from 0.4% to 11% worldwide [1]. The definitions of subclinical and overt hypothyroidism vary and this
may account for some of the different reports of prevalence.
In addition, each laboratory should have its own pregnancyspecific reference ranges for thyroid function tests. Current
American Endocrine Society (AES) Guidelines define overt
hypothyroidism during the first trimester of pregnancy as a
patient with a serum TSH level > 10 mIU/L with or without a

subnormal serum free thyroxine (FT4) level and subclinical
hypothyroidism (SCH) as a patient with a serum TSH level
> 2.5 mIU/L with a normal free T4 level [2]. The American
Thyroid Association (ATA) defines SCH as a TSH between
2.5 and 10 mIU/L with a normal FT4 concentration [1].
Early detection is important because SCH has been associated with numerous adverse effects on the outcome of pregnancy such as increased rates of preeclampsia, gestational
diabetes, preterm birth, induction of labour, and caesarean
section [3, 4].
Autoimmune thyroid disease (AITD), characterized by
raised antibodies to either thyroperoxidase (TPOAb) or
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thyroglobulin (TGAb), also has a reasonably high prevalence
during pregnancy and varies widely from 5 to 15% [3].
Elevated circulating levels of thyroid antibodies may not necessarily be associated with thyroid dysfunction but, in their
own right, have been associated with an increase in various
adverse outcomes of pregnancy and have been suggested as
being independent markers for at-risk pregnancies [5]. The
mechanism for the adverse outcomes and at what concentration this occurs are not fully understood.
We therefore sought to determine possible beneficial
effects of thyroxine treatment for overt and subclinical hypothyroidism on adverse maternal and fetal outcomes in pregnancy compared with an untreated euthyroid control group
and also determine possible independent adverse effects in
those women who were thyroid autoantibody positive.
Objective. The primary objective of the study, undertaken in
a private obstetrical practice in Sydney, was to determine
the outcomes of those pregnancies in patients who had been
treated with thyroxine for subclinical and overt hypothyroidism and compare them to the outcomes in untreated
patients with normal TSH levels. The secondary objective was
to assess the effect of thyroid autoimmunity in both groups.

2. Materials and Methods
This study was performed in a private practice setting in
North Western Sydney between 2013 and 2016 where 1025
new consecutive antenatal patients were reviewed in their
first trimester and relevant information about these patients
results of investigations was provided in the initial published
report [6]. This population group is from middle to upper
socioeconomic group and all were nonsmokers. None were
taking any form of thyroid hormone replacement therapy.
Data was not recorded on ethnicity and a previous history of
small for gestational age (SGA) babies. At the time of initial
booking with the clinic, between 7 and 11 weeks of gestation,
the routine antenatal investigations were performed. At the
same time, assessment of thyroid function was performed
by measurement of TSH and FT4 levels, TGAb and TPOAb.
Patients were considered to have SCH if the TSH was
>2.5 mIU/L but <10.0 mIU/L with a normal FT4 level and
overt hypothyroidism if the TSH was >10.0 mIU/L regardless
of the FT4 level. Few patients with a TSH < 2.5 mIU/L and
a subnormal FT4 level were classified as “isolated hypothyroxinemia” and were not treated as hypothyroid. Mothers
were considered to be antibody positive if either the TGAb
or the TPOAb were >60 IU/mL. All those with a raised TSH
(>2.5 mIU/L) were initially treated with thyroxine 50 ug daily
to keep the TSH level ≤ 2.5 mIU/L, as recommended by
the American Endocrine Society Guidelines (1). Thyroxine
replacement was continued throughout pregnancy, with TSH
monitoring every 4 weeks in the first and second trimester
and once in the third trimester. Adjustment of dosage was
made appropriately to maintain serum TSH levels between
0.1 mIU/L and 2.5 mIU/L. Patients with a TSH of ≤2.5 mIU/L,
regardless of FT4 level, were considered euthyroid and were
not treated. A glucose challenge test was performed between
26 and 28 weeks of gestation on all women using a one-hour
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nonfasting sugar level after a 50 gm load, as suggested at that
time by the Australian Diabetes in Pregnancy Association
(ADIPS). A full glucose tolerance test was only performed
if the challenge glucose response was ≥7.8 mmol/L. The
medical records of each patient were then reviewed at the
end of the pregnancy. Maternal antenatal conditions such as
pregnancy induced hypertension, antepartum haemorrhage,
and abruption of the placenta were recorded. Documentation
of fetal outcomes of each pregnancy included information on
premature labour (birth < 37 completed weeks of gestation),
premature rupture of the membranes, SGA (birth weight less
than 10th centile according to the World Health Organization
(WHO) customized fetal growth charts), stillbirth, fetal death
in utero, and caesarean section.
Informed consent was obtained from each woman who
participated in this study. Women with multiple pregnancies
were excluded from the study. All women were routinely
prescribed iodine supplementation from the time of first
presentation to eliminate any possible adverse effects of
iodine deficiency on the pregnancy.
We were unable to have an untreated control group,
as this study would not have gained ethics approval. Our
hospital guidelines follow those of the AES which recommend treatment for all pregnant women, thyroid antibody
positive or not, with thyroxine [2]. We do note that the
ATA recommends treatment for only those patients who
have a raised TSH and positive thyroid antibodies [1]. Other
authoritative sources also recommend universal treatment of
patients with SCH in pregnancy [1]. Therefore, our control
group was the untreated euthyroid pregnant patients.
The Ethics Committee of the Sydney West Area Health
Service and the Human Research Ethics Committee of The
University of Notre Dame have approved the study.
2.1. Serum Thyroid Stimulating Hormone (TSH) and Thyroid
Antibody Measurements. Serum TSH levels were measured
by a chemiluminescent immunoassay on the ADVIA Centaur
platform (Bayer Health Care) by Laverty Pathology laboratories in Sydney. The details of the performance of these assays
have been previously reported [6].
Quantitative thyroid antibodies were measured using
the ADVIA Centaur XP System. Thyroperoxidase antibodies
(TPOAb) and anti-thyroglobulin (TGAb) antibodies were
considered positive above a level of 60 international units
(IU)/mL as recommended by the manufacturer (Siemens).
All laboratory determinations were carried out in the same
laboratory. The results of serum TSH and thyroid antibody
testing have previously been reported [6].
2.2. Statistical Analysis. The statistical software package IBM
SPSS v22 was used to analyse the data. Two-tailed tests
with a significance level of 5% were used throughout. Chisquared or Fisher’s exact tests, as appropriate, were used to
test for association between categorical variables. Odds ratios
and their 95% confidence intervals (95% CI) were used to
quantify the extent of association with dichotomous outcomes. The Mann–Whitney test or Kruskal-Wallis nonparametric analysis of variance was used to test for differences in
the distribution of continuous variables by group. Spearman’s
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Table 1: A comparison of pregnancy outcomes in patients with initial serum TSH ≤ 2.5 mIU/L (𝑛 = 933) and those with serum TSH >
2.5 mIU/L who were treated with thyroxine (𝑛 = 92).
Variable
TGAb > 60 IU/mL
TPOAb > 60 IU/mL
GTT positive (GD)
Nulliparous
APGAR 1 minute < 7
APGAR 5 minutes < 7
Fetal death in utero (<26 weeks)
Stillbirth or FDIU
Pregnancy induced hypertension
Premature labour
Antepartum haemorrhage
Abruption
SROM
SGA

Initial TSH ≤ 2.5 mIU/L
(𝑁 = 933)
𝑛
%
111
11.9
141
15.1
36
3.9
346
37.2
32
3.5
7
0.8
5
0.5
13
1.4
18
1.9
16
1.7
5
0.5
1
0.1
19
2.0
14
1.5

Initial TSH > 2.5 mIU/L
(𝑁 = 92)
𝑛
%
28
30.1
46
49.5
3
3.2
37
40.2
1
1.1
0
0.0
0
0.0
1
1.1
2
2.2
3
3.2
0
0.0
0
0.0
1
1.1
4
4.3

𝑝 value

Odds ratio

LC

UC

0.001
0.001
0.760
0.574
0.220
0.402
0.479
0.800
0.884
0.304
0.479
0.752
0.522
0.050

3.2
5.5
0.8
1.1
0.3
0.9
0.9
0.8
1.1
1.9
0.9
0.9
0.5
2.9

2.0
3.5
0.3
0.7
0.1
0.9
0.9
0.1
0.3
0.6
0.9
0.9
0.7
1.0

5.2
8.6
2.8
1.8
2.3
0.9
0.9
5.9
4.9
6.7
0.9
0.9
4.0
9.1

TSH, thyroid stimulating hormone; TGAb, anti-thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; SROM, spontaneous rupture of membranes;
SGA, small for gestational age; FDIU, fetal death in utero.

rank correlation (𝑟) was used to quantify the degree of association between continuous and ordered categorical variables.

3. Results
There was a total of 1025 patients of whom 382 (37.5%) were
nulliparous. 10.1% had a TSH level > 2.5 mIU/L. Eighty-seven
women (8.5%) had TSH levels > 2.5 and ≤5 mIU/L, while
twelve women (1.2%) had a TSH > 5 and ≤10 mIU/L. There
were 4 patients (0.4%) with a TSH greater than 10 mIU/L.
18.2% had raised TPOAb and 13.6% had raised TGAb levels.
Both antibodies were detected in 88 patients (8.6%) (95%
CI 7.0% to 10.5%), and 18.2% had at least one raised thyroid
antibody.
The mean maternal age in the untreated group was 35
years (SD 5.2) and that of the treated group 33.47 years (SD
1.41). There was a statistically significant difference between
the age groups (𝑝 = 0.002); but, while this is statistically significant, a difference of 2 years is not clinically important in
these patients. The mean body weight was 70.16 kg (SD 18.96)
in the untreated group and 70.01 kg (SD 0.71) in the treated
patients, with no significant difference existing between these
2 groups (𝑝 = 0.28). A normal vaginal delivery occurred in
574 patients (56%) and with forceps or vacuum extraction
in 120 patients (11.7%). There was no significant difference in
caesarean section rate of 30.02% in the untreated group and
35.6% in the treated group (𝑝 = 0.41).
Gestational diabetes was recorded in 39 patients (3.8%).
The prevalence of pregnancy induced hypertension (hypertension developing after 20 weeks of gestation) was 2% (20
patients). Premature labour occurred in 19 patients (1.9%),
antepartum haemorrhage in 5 (0.5%), abruption of the placenta in 1 patient (0.1%), premature rupture of the membranes
in 20 (2.0%), and SGA in 18 (1.8%) of patients. A stillbirth or

fetal death in utero (>20 weeks of gestation) occurred in 14
patients (1.4%) (Table 1).
There was no statistically significant difference between
the group of thyroxine treated hypothyroid patients and
untreated euthyroid women in documented complications of
pregnancy, such as pregnancy induced hypertension, antepartum haemorrhage, abruption of the placenta, premature
labour, and premature rupture of membranes. However, prevalence of SGA occurred in 4.3% of the 92 pregnancies in the
treated group and was close to significance (𝑝 = 0.050) (4.3%
versus 1.5%), (Table 1).
The outcomes of pregnancy in those patients with any
raised antibody are shown in Table 2 with no statistically
significant associations with adverse outcomes of pregnancy.
Table 3 shows the outcomes of pregnancy in the group of
women who had at least one raised antibody (TPOAb or
TGAb). In this group, none of the parameters reached any statistical significance, not even those with SGA (𝑝 = 0.443).
The numbers were statistically too small to do a subanalysis on those patients with clinical and chemical hypothyroidism.

4. Comment
We have recently reported a high rate of SCH and raised
thyroid antibodies in this cohort of patients [6]. We subsequently followed this cohort of patients through to delivery,
treating those with overt or SCH with thyroxine, to document
possible adverse obstetric and perinatal outcomes and to
ascertain if there was a beneficial effect of thyroxine treatment
in preventing adverse outcomes. While a number of studies have followed pregnant patients suffering from SCH to
determine adverse obstetrical and fetal outcomes, at the time
we conducted this study, there was little or no data examining

4

Journal of Thyroid Research
Table 2: A comparison of pregnancy outcomes in women with and without detectable circulating thyroid antibodies.

Variable
TGAB > 60 IU/mL
TPOAb > 60 IU/mL
TSH > 2.5
GTT positive (GD)
Nulliparous
APGAR 1 minute < 7
APGAR 5 minutes < 7
Fetal death in utero (<26 weeks)
Stillbirth or FDIU
Pregnancy induced hypertension
Premature labour
Antepartum haemorrhage
Abruption
SROM
SGA

No positive antibody
(𝑁 = 789)
𝑛
%
0
0.0
0
0.0
46
5.8
28
3.6
301
38.6
25
3.2
5
0.6
3
0.4
10
1.3
17
2.2
15
1.9
3
0.4
1
0.1
19
2.4
11
1.4

≥1 positive antibody
(𝑁 = 236)
𝑛
%
139
58.4
187
78.6
47
19.7
10
4.3
79
34.2
8
3.5
2
0.9
2
0.9
4
1.7
3
1.3
4
1.7
2
0.9
0
0.0
1
0.4
7
3.0

𝑝 value

Odds ratio

LC

UC

N/A
N/A
0.0001
0.638
0.226
0.861
0.724
0.371
0.628
0.383
0.827
0.371
0.583
0.052
0.110

0.1
0.1
4.0
1.2
0.8
1.1
1.3
2.2
1.3
0.6
0.9
2.2
0.8
0.2
2.1

0.1
0.1
2.6
0.6
0.6
0.5
0.3
0.4
0.4
0.2
0.3
0.4
0.7
0.0
0.8

0.1
0.1
6.2
2.5
1.1
2.4
7.0
13.4
4.3
2.0
2.7
13.4
0.9
1.3
5.6

TSH, thyroid stimulating hormone; TGAb, anti-thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; SROM, spontaneous rupture of membranes;
SGA. small for gestational age; FDIU, fetal death in utero.

Table 3: Pregnancy outcome with any raised antibody and with TSH < 2.5 mIU/L.
Variable
TGAb > 60 IU/mL
TPOAb > 60 IU/mL
GTT positive (GD)
Nulliparous
APGAR 1 minute < 7
APGAR 5 minutes < 7
Fetal death in utero (FDIU)
Stillbirth or FDIU
Pregnancy induced hypertension
Premature labour
Antepartum haemorrhage
Abruption
SROM
SGA

No positive antibody
(𝑁 = 742)
𝑛
%
0
0.0%
0
0.0%
28
3.8%
281
38.2%
24
3.3%
5
0.7%
3
0.4%
10
1.4%
15
2.0%
13
1.8%
3
0.4%
1
0.1%
18
2.4%
10
1.4%

≥1 positive antibody
(𝑁 = 191)
𝑛
%
111
58.1
141
73.8
7
3.7
62
33.5
8
4.3
2
1.1
2
1.1
3
1.6
3
1.6
3
1.6
2
1.1
0
0.0
1
0.5
4
2.1

𝑝 value
NA
NA
0.956
0.236
0.495
0.582
0.274
0.807
0.694
0.817
0.274
NA
0.990
0.443

Odds ratio

LC

UC

1.0
0.8
1.3
1.6
2.6
1.2
0.8
0.9
2.6

0.4
0.6
0.6
0.3
0.4
0.3
0.2
0.3
0.4

2.3
1.1
3.0
8.2
15.8
4.3
2.7
3.2
15.8

0.2
1.6

0.0
0.5

1.6
5.1

TSH, thyroid stimulating hormone; TGAb, anti-thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; SROM, spontaneous rupture of membranes;
SGA, small for gestational age; FDIU, fetal death in utero.

the possible beneficial effects of thyroxine treatment in
preventing adverse outcomes.
Reference ranges for TSH during the first trimester of pregnancy remain controversial and there may be geographical
and ethnic factors to take into account. We have used the
reference ranges recommended by the American Endocrine
Society Guidelines with the upper limit of the euthyroid pregnant reference range in the first trimester being 2.5 mIU/L.
In a recent Cochrane review, no studies were identified
that assessed the outcome of treatment with thyroxine on

pregnant women with SCH [7]. In our study, patients with
SCH and overt hypothyroidism were treated with thyroxine
from the first antenatal visit to maintain normal thyroid
function (serum TSH 0.1–2.5 mIU/L) and we then assessed
the outcomes of pregnancy. This study was therefore different
to most previously reported studies that looked for an association or cause and effect relationship between SCH diagnosed
in the first trimester and adverse outcomes of the pregnancy.
Our affected patients were treated with thyroxine and there
was no control group of untreated hypothyroid patients, as
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our hospital current guidelines preclude nontreatment of
patients with SCH and this is also recommended by AES.
However, our control group was the untreated euthyroid
patients, who were a similar population group. Our patients
were monitored by regular TSH testing and adjustment of
thyroxine dosage to ensure that the serum TSH levels were
maintained between 0.1 mIU/L and 2.5 mIU/L.
We found no difference in outcome between our 2 groups.
However, an interesting outcome finding in this study was
that women with SCH (92 patients), even after correction
of thyroid function with thyroxine replacement therapy, had
an increased rate of SGA, 4.3% compared with 1.5% in the
euthyroid control group, but this was not statistically significant (𝑝 = 0.05) and the number of affected babies was only
4. In a recently published study, Maraka et al. from the Mayo
Clinic reported a retrospective study where they had a treated
and an untreated hypothyroid control group and showed that
SGA was significantly decreased in the thyroxine treatment
group (1.3% versus 10%; 𝑝 < 0.001) [8].
The prevalence of SGA in SCH women has been well
documented in several reviews [9, 10] and in other studies
[11, 12] but in none of these studies has the SCH been treated
at initial presentation. In spite of the fact that we treated SCH
patients with thyroxine at presentation and maintained the
serum TSH at <2.5 mIU/L throughout pregnancy, the rate of
SGA was 4.3%, raising the possibility that other factors or
mechanisms may contribute to this adverse outcome. However, this conclusion needs to be considered with caution,
as the number of women delivering babies with SGA in our
study was very small (𝑛 = 4). If there is a direct cause and
effect relationship between women suffering SCH and subsequently delivering a baby with SGA, one of the factors may
be the timing of testing and of commencement of appropriate
thyroxine therapy. Our patients presented between 7 and 11
weeks of gestation so it is possible that this delay in initiating
thyroxine replacement therapy could be a contributory factor.
We also accept that even though our patients may be a relatively homogenous group, there may have been a difference
in characteristics between the 2 groups.
The mean maternal age in the present study was 34.9 years
and this is higher than most of the other reports. This may
partly account for our higher prevalence of SCH and AITD
as both SCH and AITD have been shown to increase with age
[13]. We reported no increase in pregnancy complications in
relation to parity and Walsh and colleagues reported similar
findings [14].
No other significant adverse outcomes of pregnancy in
relation to treated SCH were documented in this study. This
is in contrast to other studies [15, 16] of untreated patients
that have shown an increase in adverse outcomes. Of interest,
is that Schneur and colleagues, also found that high TSH
levels in the first trimester in 2801 women were associated
with adverse pregnancy outcomes especially SGA. However,
the predictive accuracy was reported to be poor [17]. By contrast, Ong and colleagues, although documenting a 15%
adverse outcome rate, suggested that testing for a raised TSH
in the first trimester does not predict adverse outcomes of
pregnancy [18].
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Although increased rates of SGA have been shown to be
present in women with clinical hypothyroidism or SCH, there
have been few studies where an association between AITD
and SGA has been documented [11, 19]. Negro and colleagues
found that, in euthyroid pregnant women, who were positive
for TPOAb and received thyroxine treatment, there was
a lowering of the chances of miscarriage and premature
delivery [20] and our study supports the lower prevalence of
adverse pregnancy outcomes on thyroxine replacement.
We have shown no increase in other adverse outcomes
of pregnancy associated with the presence of increased
thyroid antibodies except for a correlation with a raised TSH
(Table 2). However, a possible association may be confounded
by the fact that patients with SCH and thyroid antibodies
were treated with thyroxine. In other studies, an increase in
the risk of placental abruption, premature labour, gestational
diabetes, and severe preeclampsia has been shown with raised
antibodies [21–25]. The prevalence of gestational diabetes in
this study is lower than reported elsewhere and this may
be due to the motivated, generally nonobese, and higher
socioeconomic status of patients in the study.
In a very recent publication and in a large study, Plowden
has shown that a high TSH level is not associated with infertility, pregnancy loss, or a decrease in live birth rate. This is different to our study as we mainly looked at the other adverse
outcomes of pregnancy [26].
The strengths of our study are that one person in a single
practice provided the obstetric care to all of the patients who
were generally from a higher socioeconomic group. Compared to reported poor outcomes of untreated patients with
SCH, we have shown no adverse outcomes after treatment.
The weaknesses of the study are that we do not have a
matched control group for the reasons provided. However, we
did compare our treated group with a large unselected group
of euthyroid pregnant women. The other weakness is the
small sample size. The present study was conducted more as
an audit to get estimates of rates of the different outcomes for
women with normal thyroid function and those treated for
SCH. As SGA is the only outcome with an appreciable difference, the power calculation was done with respect to only
SGA. To detect an increase of 2.8% in the rate of SGA from
1.5% in women without SCH to 4.3% in women with SCH,
with 80% power and a significance level of 5%, 3500 women
would be required, assuming the proportion of women with
SCH is approximately 9% (310 women with SCH and 3190
without).
Our study supports the view that thyroxine replacement
in pregnant women suffering from overt or SCH does prevent
obstetric and fetal complications and shows no harmful
effects of thyroxine therapy. However, without a matched
untreated control group, we cannot conclude that all pregnant
women with SCH should be treated with thyroxine. Negro
and Stagnaro-Green have suggested in a preliminary intervention trial that treatment of SCH in early pregnancy is
beneficial and is to be recommended [27]. If this is to become
accepted best practice, it follows that universal screening for
an elevated TSH will need to be implemented as early as possible after confirmation of conception and patients will need
to be treated and monitored throughout their pregnancies.
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